[
    [
        {
            "time": "",
            "original_text": "康龙化成(03759.HK)投资康君仲元基金 初始认缴出资2.6亿元",
            "features": {
                "keywords": [
                    "康龙化成",
                    "康君仲元基金",
                    "初始认缴",
                    "出资2.6亿元"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "康龙化成(03759.HK)投资康君仲元基金 初始认缴出资2.6亿元",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "北向资金交投趋谨慎全天净卖出不足2亿，贵州茅台连续11日遭抛售",
            "features": {
                "keywords": [
                    "北向资金",
                    "谨慎",
                    "净卖出",
                    "贵州茅台",
                    "连续11日抛售"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "白酒"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "北向资金交投趋谨慎全天净卖出不足2亿，贵州茅台连续11日遭抛售",
                "Correlation": 10,
                "Sentiment": 4,
                "Importance": 8,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 10,
                "Market_Scope": 6,
                "Time_Proximity": 9,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "财信证券医药生物行业2021年8月月度报告：坚守高景气，关注高性价比个股",
            "features": {
                "keywords": [
                    "财信证券",
                    "医药生物",
                    "高景气",
                    "高性价比个股"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "财信证券医药生物行业2021年8月月度报告：坚守高景气，关注高性价比个股",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 5,
                "Market_Scope": 7,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        }
    ]
]